Comparison of immunogenicity, safety, and efficacy of EVA71 vaccine in children: a systematic review and meta-analysis.

Expert Rev VaccinesAug 25, 2026 (epub)
Clinical ResearchPediatrics

Muhammad Gilang Dwi Putra, Rodman Tarigan Girsang, Rais Amaral Haq et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the immunogenicity, safety, and efficacy of inactivated EV-A71 vaccines in children, analyzing data from five phase III RCTs involving 36,659 participants. The study found that vaccination significantly increased seropositivity and seroconversion rates, with vaccine efficacy against EV-A71-associated HFMD exceeding 98%.

Key findings

  • Vaccination resulted in a pooled RR of 13.04 for seroconversion compared to placebo.
  • Vaccine efficacy against EV-A71-associated HFMD was over 98% (pooled RR 0.02).
  • Seropositivity increased significantly with RR 5.8 in early follow-up and RR 3.09 in medium-term follow-up.
  • Solicited adverse events were mild and comparable between vaccinated and placebo groups.

Why it matters

The findings underscore the effectiveness of EV-A71 vaccines in preventing hand, foot, and mouth disease in children, which can lead to severe complications. Understanding vaccine efficacy and safety is crucial for pediatric vaccination strategies.

Source

PubMed · PMID 42639682

Published in Expert Rev Vaccines. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.